Latest headlines

Wednesday, 7 November, 2007

Once-yearly osteo med approved

Health Canada has approved zoledronic acid (Aclasta), the first ever once-yearly treatment for postmenopausal osteoporosis sufferers, Novartis Pharmaceuticals announced in .

of the drug's efficacy back in May, when the published the results of a three-year trial of more than 7,700 women. A single 15-minute infusion of zoledronic acid reduced the risk of spine fractures by 70% and hip fractures by 41%.

"The approval of a new medication is welcome news for the millions of Canadians who have osteoporosis," said Julie Foley, President of Osteoporosis Canada in the press release. Nearly 60% of patients on daily bisphosphonate treatments and 50% of those on weekly bisphosphonate meds don't stick to their drug regimen, and it's hoped the once-a-year dosage will offer those patients a treatment option they can more easily follow.

Check out our website:


Post a Comment